1,956 Shares in Natera, Inc. $NTRA Bought by Encompass More Asset Management

Posted by George Bondi on Oct 18th, 2026

Encompass More Asset Management purchased a new position in shares of Natera, Inc. (NASDAQ:NTRA – Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 1,956 shares of the medical research company’s stock, valued at approximately $808,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in NTRA. BlackRock Inc. bought a new stake in shares of Natera during the 2nd quarter worth approximately $2,962,770,000. Arrowstreet Capital Limited Partnership grew its stake in shares of Natera by 1.0% in the first quarter. Arrowstreet Capital Limited Partnership now owns 1,191,732 shares of the medical research company’s stock valued at $238,334,000 after buying an additional 11,793 shares in the last quarter. Maverick Capital Ltd. grew its stake in shares of Natera by 24.1% in the first quarter. Maverick Capital Ltd. now owns 1,171,633 shares of the medical research company’s stock valued at $234,315,000 after buying an additional 227,605 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Natera by 10.7% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 833,376 shares of the medical research company’s stock valued at $226,220,000 after buying an additional 80,440 shares in the last quarter. Finally, Bank of America Corp DE acquired a new position in Natera during the second quarter worth $199,960,000. Institutional investors own 99.90% of the company’s stock.

Wall Street Analyst Weigh In

NTRA has been the topic of several analyst reports. BTIG Research upped their price target on shares of Natera from $290.00 to $320.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Guggenheim increased their price target on shares of Natera from $360.00 to $475.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. Royal Bank Of Canada lifted their price objective on shares of Natera from $350.00 to $460.00 and gave the company an “outperform” rating in a research report on Friday, September 25th. UBS Group lifted their price objective on shares of Natera from $290.00 to $435.00 and gave the company a “buy” rating in a research report on Wednesday, September 9th. Finally, TD Cowen boosted their price objective on shares of Natera from $340.00 to $480.00 and gave the stock a “buy” rating in a research note on Tuesday. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Natera presently has an average rating of “Moderate Buy” and an average price target of $368.69.

Read Our Latest Report on Natera

Insiders Place Their Bets

In other Natera news, insider John Fesko sold 6,517 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $321.53, for a total transaction of $2,095,411.01. Following the completion of the sale, the insider owned 197,257 shares of the company’s stock, valued at $63,424,043.21. This trade represents a 3.20% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Michael Brophy sold 2,419 shares of Natera stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $253.96, for a total transaction of $614,329.24. Following the transaction, the chief financial officer directly owned 54,295 shares of the company’s stock, valued at approximately $13,788,758.20. This trade represents a 4.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 52,985 shares of company stock valued at $16,119,137 over the last 90 days. 5.05% of the stock is owned by insiders.

Natera Stock Down 2.8%

NASDAQ:NTRA opened at $393.44 on Friday. The stock’s 50 day moving average price is $358.21 and its two-hundred day moving average price is $275.25. The firm has a market capitalization of $56.71 billion, a price-to-earnings ratio of -289.29 and a beta of 1.50. Natera, Inc. has a 12-month low of $178.01 and a 12-month high of $437.41.

Natera (NASDAQ:NTRA – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.02. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%. The company had revenue of $752.75 million during the quarter, compared to analysts’ expectations of $661.24 million. During the same period last year, the firm posted ($0.74) earnings per share. The business’s revenue was up 37.7% on a year-over-year basis. Equities research analysts expect that Natera, Inc. will post -1.05 EPS for the current year.

Natera Profile

(Free Report)

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to assess genetic and disease-related risks. The company uses technologies including cell-free DNA analysis and next-generation sequencing to support clinical decision-making in reproductive health, oncology and organ transplantation.

Its reproductive health offerings include Panorama, a noninvasive prenatal test that screens for certain chromosomal conditions, and Horizon, a carrier screening test that evaluates whether prospective parents carry genetic variants associated with inherited disorders.